Terms

These Terms govern use of TrialSign, a clinical intelligence advisory service available at https://intelligencetrials.com.

If you use the service on behalf of an organisation, you confirm that you have authority to share inquiry information and engage in scoping discussions for that organisation.

TrialSign provides research intelligence and strategic scientific analysis for professional biotech diligence and strategy.

Outputs are not medical advice, legal advice, regulatory advice, patent advice or investment advice.

No advisory work begins until scope, deliverables, timing, fee, confidentiality requirements and any client-provided materials have been agreed in writing.

Deliverables may include an Executive Decision Book, Scientific Evidence Dossier or Private Intelligence Room depending on the agreed scope.

Clinical trial records, publications, regulatory materials, patent references and company disclosures may be incomplete, delayed, changed or unavailable.

Important findings should be checked against primary sources and reviewed with qualified professional advisors before reliance in regulated, legal, patent, medical or investment contexts.

Confidential or unpublished materials should only be shared after appropriate confidentiality arrangements are agreed.

Public evidence and client-provided materials remain clearly distinguished throughout the engagement where relevant.

TrialSign, its report formats, workflow design, structured methods and non-public components are protected where applicable.

Public source records remain subject to the rights and terms of the original source providers.

TrialSign does not guarantee that every relevant source, trial, publication, regulatory document, company signal or patent reference will be identified in every engagement.

Evidence gaps, assumptions and limitations are part of the deliverable and should be considered before decisions are made.

General inquiries: support@intelligencetrials.com.